

# TARPSWG Clinical Trials Committee

Christina L. Roland, MD, MS

MD Anderson Cancer Center

# Core Committee-1<sup>st</sup> meeting 9/2020

<b>Dario Callegaro-Milan</b>	<b>Miheala Druta-Tampa</b>
<b>Chan Raut-Boston</b>	<b>Herbert Loong-Hong Kong</b>
<b>Ken Cardona-Atlanta</b>	<b>Michael Wagner-Seattle</b>
<b>Winan van Houdt-Amsterdam</b>	<b>Angela Hong-Sydney</b>
<b>Carol Swallow-Toronto</b>	<b>Andrew Bishop-Houston</b>
<b>David Gyorki-Melbourne</b>	<b>Nicole Larrier-Duke</b>
<b>Samuel Ford-Birmingham</b>	<b>Mateusz Spalek-Warsaw</b>
<b>Miles Smith-London</b>	<b>Sally Burtenshaw-Toronto</b>
<b>Neha Goel-Miami</b>	<b>Sylvie Bonvalot-Paris</b>
<b>Sinziana Dumitra-Montreal</b>	<b>Carolyn Nessim-Ottawa</b>

# Additional Committee Members

<b>Marco Fiore-Milan</b>	<b>Hanna Kosela-Paterczyk-Warsaw</b>
<b>Mark Fairweather-Boston</b>	<b>Celso Mello-Sau Paulo</b>
<b>Tom Chen-Taiwan</b>	<b>Matt Spraker-St. Louis</b>
<b>Michael Nathenson-Boston</b>	<b>Arthur Hung-Oregon</b>
<b>Vicenzi Bruno-Rome</b>	<b>Miranda Lam-Boston</b>
<b>Cklaudia Valverde Morales-Barcelona</b>	<b>Edward Kim-Seattle</b>
<b>Richard Riedel-Duke</b>	<b>Bernd Kasper-Manheim</b>
<b>Gina D'Amato-Miami</b>	<b>Giovanni Grignani-Torino</b>

# Committee Goals

- Large/long-term projects
  - Involve large portion of TARPSWG
    - Multiple continents
  - Years to activate/complete
  - ?parallel protocols
- Short-term projects
  - Low-hanging fruit
  - A few institutions
  - Background data for larger concepts

# Initial Concepts

- Long-term
  - phase 3 exploring RT +/- trabectedin in retroperitoneal liposarcoma
    - Dario Callegaro will give background at next meeting to begin discussion/brain storming
  - Preop RT for recurrent RPS
    - Probably not Phase III RCT
    - Angela Hong working through this concept
  - \*re-excision after whoops surgery-form separate group since extremity/trunk
- Short-term
  - SBRT for low-volume recurrence
    - Andrew Bishop, Mateisz Spalek & Ken Cardona
      - REC: retrospective data first
      - Generate prospective protocol after looking at current practice, outcomes, etc

# Additional Concepts

- Deep local/regional hyperthermia + chemotherapy vs chemotherapy alone in unresectable/metastatic RPS
- Master protocol for Window of opportunity trials
- Amgen MDM2 inhibitor AMG232 + standard radiation therapy
- Simultaneous integrated boost radiation therapy vs. surgery alone
  - Perhaps NCI cooperative group
- Role of systemic chemotherapy in stage IV STS after rendering NED
- Immunotherapy RP protocol
- imaging study for surveillance

# Comments/questions

[clroland@mdanderson.org](mailto:clroland@mdanderson.org)